For example, ADCs with bispecific antibodies targeting HER-2 and the prolactin receptor have been shown to improve ADC internalisation and have higher anti-tumour activity in vitro compared to a conventional HER2-directed ADC [132]. This evidence concerns the gene ERBB2 and neoplasm.